Sign in Subscribe

Archive

A collection of 370 issues

Latest

Case-control study compares metabolic and laboratory biomarkers in early-onset versus late-onset colorectal cancer

Skip to content The CRC Digest Case-control study compares metabolic and laboratory biomarkers in early-onset versus late-onset colorectal cancer Researchers used a large US database to compare metabolic, inflammatory, and laboratory abnormalities between patients diagnosed at ages 18-49 versus 50-75. (Cancers) This content is informational only and does not constitute

First Nations people in Ontario experience higher colon cancer incidence at younger ages

Skip to content The CRC Digest First Nations people in Ontario experience higher colon cancer incidence at younger ages New evidence shows registered First Nations people have higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than other Ontario residents. (The Lancet

Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency

Skip to content The CRC Digest ◇ RESEARCH Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency A study of 794 colorectal and endometrial cancer cases evaluated whether a single-section test could accurately identify deficient mismatch repair (dMMR) status. (Human Pathology) This content is informational only

Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer

Skip to content The CRC Digest ▸ TREATMENT Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute

Systematic review and meta-analysis quantifies sensitivity and specificity of fecal immunochemical testing and colonoscopy for colorectal cancer screening

Skip to content The CRC Digest ▪ SCREENING Systematic review and meta-analysis quantifies sensitivity and specificity of fecal immunochemical testing and colonoscopy for colorectal cancer screening Researchers analyzed multiple studies to estimate the accuracy of two major screening tests in asymptomatic average-risk adults. (Preventive Medicine Reports) This content is informational only

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This

CRC Research Update — July 18, 2026

Today's colorectal cancer research highlights

Study reveals sex-specific metabolic comorbidity patterns in CRC patients

Skip to content The CRC Digest Study reveals sex-specific metabolic comorbidity patterns in CRC patients Researchers explored sex-specific prevalence and co-occurrence of Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease among CRC patients using electronic medical records. (Front Med) This content is informational only and does not constitute medical

Baseline ctDNA analyzed for thrombotic risk in locally advanced rectal cancer

Skip to content The CRC Digest Baseline ctDNA analyzed for thrombotic risk in locally advanced rectal cancer Plasma ctDNA was analyzed by droplet digital PCR for tumor-specific mutations including KRAS, NRAS, BRAF, and PIK3CA to explore association with VTE occurrence. (Cancer Treat Res Commun) This content is informational only and

Salivary microbiome evaluated as non-invasive screening tool for early-onset CRC

Skip to content The CRC Digest Salivary microbiome evaluated as non-invasive screening tool for early-onset CRC High-throughput 16S ribosomal RNA gene sequencing of saliva samples showed distinct microbiota profiles in EOCRC patients compared to controls. (BMC Microbiol) This content is informational only and does not constitute medical advice. Always consult